The United States Pharmacopeia retired General Chapter <1120> Raman Spectroscopy on 1 August 2020 and replaced it with a paired structure: <858> as the official compendial chapter that any monograph can cite as a test method, and <1858> Raman Spectroscopy - Theory and Practice as the informational companion. The change formalised what had been working practice for a decade. Raman moved from “describe your validation in the monograph” to “cite the chapter”.
Five and a half years in, the split has done most of what it was designed to do. Identification monographs that previously specified an infrared procedure now routinely accept a Raman procedure performed under <858>, and laboratories no longer have to defend the basics of laser-line selection, fluorescence handling, or wavenumber calibration on first principles. The compendial language now does that work.
What has been slower is what always is slower: rewriting monographs. The USP-NF notice that accompanied the renumbering listed dozens of monographs whose <1120> citation had to be updated by reference. Most of those changes were mechanical, but the broader question - which monographs should add Raman as a permitted identity procedure - is a per-substance decision, and the queue moves through stimuli articles and public comment one substance at a time.
What the chapter pair actually says
<858> is short by design. It scopes Raman as a qualitative identification technique and a quantitative measurement technique, sets wavelength-axis accuracy criteria, addresses laser intensity stability, and points to the informational chapter for everything that is not a pass/fail acceptance criterion. The structure mirrors the broader spectroscopy modernisation that USP applied across infrared, near-infrared, and ultraviolet/visible: a clean compendial chapter that monographs can cite, with the methodological commentary lifted out into the 1000-series companion.
<1858> carries the substance. It covers system suitability, the qualitative versus quantitative split, the practical limits of fluorescent matrices, the role of solid-state versus diode lasers, and a section on specialised techniques including surface-enhanced and resonance Raman. It is the chapter analysts read once and refer back to; <858> is the one auditors check.
Where the chapters land in monograph practice
The most visible monograph effect is in identity testing of incoming raw materials. The compendial route was always open under <1120>, but <858>‘s explicit scoping and the parallel maturation of handheld Raman instruments tipped the operating economics. A 2019 PDA Journal study reported on a handheld Raman programme that achieved 100% correct positive identification and a 99.9% correct rejection rate across roughly 40,000 challenges using a library of 198 raw materials. That kind of data is what convinced quality units that 100% container identification could replace statistical sampling on incoming lots.
Where the chapters have not pushed as hard is in quantitative monograph testing. Assay determinations against a Raman procedure remain rare, and the cases that exist are mostly polymorph and crystal-form work where the spectroscopy is the most discriminating tool available. The infrared, HPLC, and titrimetric procedures that anchor most monograph assays were not displaced; <858> simply makes it easier to add Raman as an alternative where the chemistry supports it. Sites weighing the choice between vibrational techniques generally use the Raman versus NIR decision framework at the project-scoping stage rather than after a chapter citation has been written into a monograph.
The handheld identity-testing workhorse
In day-to-day quality operations, the chapter pair underwrites a specific use case more than any other: handheld Raman, container-by-container, at goods-in. Sites that ran Raman for identification before 2020 generally continued to do so; sites that came later had a clearer compendial path. The growth has been in the second cohort - generics manufacturers, contract manufacturers handling many small lots, and warehouses where physical access to the container is easier than transport to a central lab.
The methodological discipline that <1858> brings to those programmes is concrete. System suitability is no longer a local procedure invented for one site’s instrument; it is checked against compendial-level expectations for wavelength accuracy and intensity reproducibility. The audit conversation moved from “show me your validation report” to “show me your last <858> system suitability run”.
What stayed ambiguous
Two areas continue to generate questions in inspections and at industry meetings.
The first is the boundary between compendial Raman identification under <858> and process Raman used in continuous or batch manufacturing. <858> is a laboratory test method; in-line and at-line process Raman is governed by the broader PAT framework. Most companies handle the gap by keeping the two operating modes administratively separate, but for an integrated continuous manufacturing line the distinction is artificial. ICH Q14 closed part of that gap on the analytical procedure development side; the compendial chapters did not.
The second is library transfer. Methods developed on one handheld instrument do not always transfer cleanly to another, even within a single vendor’s product range. <858> addresses wavelength accuracy and intensity reproducibility but does not prescribe a transfer protocol. PDA, ASTM, and several pharmacopoeial subgroups have circulated draft language; none of it has reached compendial status yet.
Five-year readout
The compendial scaffolding works. Auditors know what to ask for; analysts know what to deliver. Adoption beyond raw-material identification is slower, and the open methodological questions are the ones the chapter pair quietly deferred to the informational companion. For pharmaceutical sites planning a Raman programme in 2026, the chapter pair is the floor, not a goal, and the next round of monograph-level work is where the practical scope will widen.